

13.09.18

NEWS RELEASE

ADMEDUS WELCOMES NEW OPPORTUNITIES IN EMERGING MARKETS

Admedus Limited (ASX:AHZ), is pleased to announce recent developments in the Emerging Markets with the introduction of CardioCel® to Vietnam and regulatory approval granted for CardioCel 3D® in the United Arab Emirates (UAE).

Vietnam

Admedus has received regulatory approval and first orders for CardioCel® in Vietnam. With a population of 95 million people, and approximately 15000 children born each year with CHD¹, Vietnam is emerging as a potentially substantial market in Asia Pacific.

“Due to its prolific population and developing socio-economic status, Asia is a key territory of opportunity for our ADAPT® technology and expanding product portfolio,” said CEO Wayne Paterson.

“We are working to build networks with leading clinicians and major cardiac centres in the region; recently hosting highly engaged, leading cardiologists at an Experts Meeting with Admedus’ KOLs during the 7th Congress of the Asia Pacific Paediatric Cardiac Society in Indonesia. The launch of CardioCel® into Vietnam demonstrates the effectiveness of this strategy as we continue to make inroads in these emerging markets.”

United Arab Emirates

The UAE is a strategically important centre within the Middle East and North African (MENA) region for performing cardiovascular surgery and is the first MENA country to introduce Admedus’ ground-breaking CardioCel 3D® product.

Launched in North America in January, CardioCel 3D is a disruptive technology in the high-complexity congenital defect repair space. Its unique pre-shaped curve enables surgeons to

Admedus Limited

Registered Office:

Level 9, 301 Coronation Drive, Milton, Queensland 4064


Customer Service:

T: 1300 550 310 F: 1300 880 398 International: T: +61 (0)7 3152 3200 F: +61 (0)7 3152 3299

E: info@admedus.com W: admedus.com

Brisbane • Minneapolis • Geneva • Singapore

ABN 35 088 221 078



¹ Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002;39:1890–900.



achieve a more natural shape, allowing for optimal compliance and dynamics, while simultaneously providing the superior clinical benefits of our ADAPT® technology to deliver transformative healing.

“We are working diligently to break new ground and drive the demand for our clinically-superior ADAPT® technology in new and developing markets with high levels of unmet need and commercial potential,” CEO Wayne Paterson said.

ENDS

About Admedus Limited

Admedus (ASX:AHZ) is a medical technologies company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Website: www.admedus.com

Facebook: www.facebook.com/Admedus

Twitter: [@Admedus](https://twitter.com/Admedus)

For more information, please contact:

Admedus Limited

Barbara Ferres

Communications Manager

+61 7 3152 3216

communications@admedus.com

